The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Radiopharmaceutical (Oral Route) Market Research Report 2025
Synopsis
The global Radiopharmaceutical (Oral Route) market was valued at US$ 6761 million in 2023 and is anticipated to reach US$ 8804.1 million by 2030, witnessing a CAGR of 3.9% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Radiopharmaceutical (Oral Route), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Radiopharmaceutical (Oral Route).
Report Scope
The Radiopharmaceutical (Oral Route) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Radiopharmaceutical (Oral Route) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Radiopharmaceutical (Oral Route) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bracco Imaging
Bayer
Mallinckrodt
Nordion
Triad Isotopes
Lantheus
IBA Group
GE Healthcare
China Isotope & Radiation
Jubilant Pharma
Eli Lilly
Advanced Accelerator Applications
SIEMENS
Dongcheng
Navidea
Segment by Type
Actinium-225
Lutetium-177
Radium-223
Holmium-166
Other
Segment by Application
Oncology
Cardiology
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Radiopharmaceutical (Oral Route) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Radiopharmaceutical (Oral Route) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Radiopharmaceutical (Oral Route) market was valued at US$ 6761 million in 2023 and is anticipated to reach US$ 8804.1 million by 2030, witnessing a CAGR of 3.9% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Radiopharmaceutical (Oral Route), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Radiopharmaceutical (Oral Route).
Report Scope
The Radiopharmaceutical (Oral Route) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Radiopharmaceutical (Oral Route) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Radiopharmaceutical (Oral Route) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bracco Imaging
Bayer
Mallinckrodt
Nordion
Triad Isotopes
Lantheus
IBA Group
GE Healthcare
China Isotope & Radiation
Jubilant Pharma
Eli Lilly
Advanced Accelerator Applications
SIEMENS
Dongcheng
Navidea
Segment by Type
Actinium-225
Lutetium-177
Radium-223
Holmium-166
Other
Segment by Application
Oncology
Cardiology
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Radiopharmaceutical (Oral Route) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Radiopharmaceutical (Oral Route) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Radiopharmaceutical (Oral Route) Market Overview
1.1 Product Overview and Scope of Radiopharmaceutical (Oral Route)
1.2 Radiopharmaceutical (Oral Route) Segment by Type
1.2.1 Global Radiopharmaceutical (Oral Route) Market Value Comparison by Type (2024-2030)
1.2.2 Actinium-225
1.2.3 Lutetium-177
1.2.4 Radium-223
1.2.5 Holmium-166
1.2.6 Other
1.3 Radiopharmaceutical (Oral Route) Segment by Application
1.3.1 Global Radiopharmaceutical (Oral Route) Market Value by Application: (2024-2030)
1.3.2 Oncology
1.3.3 Cardiology
1.3.4 Other
1.4 Global Radiopharmaceutical (Oral Route) Market Size Estimates and Forecasts
1.4.1 Global Radiopharmaceutical (Oral Route) Revenue 2019-2030
1.4.2 Global Radiopharmaceutical (Oral Route) Sales 2019-2030
1.4.3 Global Radiopharmaceutical (Oral Route) Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Radiopharmaceutical (Oral Route) Market Competition by Manufacturers
2.1 Global Radiopharmaceutical (Oral Route) Sales Market Share by Manufacturers (2019-2024)
2.2 Global Radiopharmaceutical (Oral Route) Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Radiopharmaceutical (Oral Route) Average Price by Manufacturers (2019-2024)
2.4 Global Radiopharmaceutical (Oral Route) Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Radiopharmaceutical (Oral Route), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Radiopharmaceutical (Oral Route), Product Type & Application
2.7 Radiopharmaceutical (Oral Route) Market Competitive Situation and Trends
2.7.1 Radiopharmaceutical (Oral Route) Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Radiopharmaceutical (Oral Route) Players Market Share by Revenue
2.7.3 Global Radiopharmaceutical (Oral Route) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Radiopharmaceutical (Oral Route) Retrospective Market Scenario by Region
3.1 Global Radiopharmaceutical (Oral Route) Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Radiopharmaceutical (Oral Route) Global Radiopharmaceutical (Oral Route) Sales by Region: 2019-2030
3.2.1 Global Radiopharmaceutical (Oral Route) Sales by Region: 2019-2024
3.2.2 Global Radiopharmaceutical (Oral Route) Sales by Region: 2025-2030
3.3 Global Radiopharmaceutical (Oral Route) Global Radiopharmaceutical (Oral Route) Revenue by Region: 2019-2030
3.3.1 Global Radiopharmaceutical (Oral Route) Revenue by Region: 2019-2024
3.3.2 Global Radiopharmaceutical (Oral Route) Revenue by Region: 2025-2030
3.4 North America Radiopharmaceutical (Oral Route) Market Facts & Figures by Country
3.4.1 North America Radiopharmaceutical (Oral Route) Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Radiopharmaceutical (Oral Route) Sales by Country (2019-2030)
3.4.3 North America Radiopharmaceutical (Oral Route) Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Radiopharmaceutical (Oral Route) Market Facts & Figures by Country
3.5.1 Europe Radiopharmaceutical (Oral Route) Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Radiopharmaceutical (Oral Route) Sales by Country (2019-2030)
3.5.3 Europe Radiopharmaceutical (Oral Route) Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Radiopharmaceutical (Oral Route) Market Facts & Figures by Country
3.6.1 Asia Pacific Radiopharmaceutical (Oral Route) Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Radiopharmaceutical (Oral Route) Sales by Country (2019-2030)
3.6.3 Asia Pacific Radiopharmaceutical (Oral Route) Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Radiopharmaceutical (Oral Route) Market Facts & Figures by Country
3.7.1 Latin America Radiopharmaceutical (Oral Route) Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Radiopharmaceutical (Oral Route) Sales by Country (2019-2030)
3.7.3 Latin America Radiopharmaceutical (Oral Route) Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Radiopharmaceutical (Oral Route) Market Facts & Figures by Country
3.8.1 Middle East and Africa Radiopharmaceutical (Oral Route) Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Radiopharmaceutical (Oral Route) Sales by Country (2019-2030)
3.8.3 Middle East and Africa Radiopharmaceutical (Oral Route) Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Radiopharmaceutical (Oral Route) Sales by Type (2019-2030)
4.1.1 Global Radiopharmaceutical (Oral Route) Sales by Type (2019-2024)
4.1.2 Global Radiopharmaceutical (Oral Route) Sales by Type (2025-2030)
4.1.3 Global Radiopharmaceutical (Oral Route) Sales Market Share by Type (2019-2030)
4.2 Global Radiopharmaceutical (Oral Route) Revenue by Type (2019-2030)
4.2.1 Global Radiopharmaceutical (Oral Route) Revenue by Type (2019-2024)
4.2.2 Global Radiopharmaceutical (Oral Route) Revenue by Type (2025-2030)
4.2.3 Global Radiopharmaceutical (Oral Route) Revenue Market Share by Type (2019-2030)
4.3 Global Radiopharmaceutical (Oral Route) Price by Type (2019-2030)
5 Segment by Application
5.1 Global Radiopharmaceutical (Oral Route) Sales by Application (2019-2030)
5.1.1 Global Radiopharmaceutical (Oral Route) Sales by Application (2019-2024)
5.1.2 Global Radiopharmaceutical (Oral Route) Sales by Application (2025-2030)
5.1.3 Global Radiopharmaceutical (Oral Route) Sales Market Share by Application (2019-2030)
5.2 Global Radiopharmaceutical (Oral Route) Revenue by Application (2019-2030)
5.2.1 Global Radiopharmaceutical (Oral Route) Revenue by Application (2019-2024)
5.2.2 Global Radiopharmaceutical (Oral Route) Revenue by Application (2025-2030)
5.2.3 Global Radiopharmaceutical (Oral Route) Revenue Market Share by Application (2019-2030)
5.3 Global Radiopharmaceutical (Oral Route) Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Bracco Imaging
6.1.1 Bracco Imaging Corporation Information
6.1.2 Bracco Imaging Description and Business Overview
6.1.3 Bracco Imaging Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Bracco Imaging Radiopharmaceutical (Oral Route) Product Portfolio
6.1.5 Bracco Imaging Recent Developments/Updates
6.2 Bayer
6.2.1 Bayer Corporation Information
6.2.2 Bayer Description and Business Overview
6.2.3 Bayer Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Bayer Radiopharmaceutical (Oral Route) Product Portfolio
6.2.5 Bayer Recent Developments/Updates
6.3 Mallinckrodt
6.3.1 Mallinckrodt Corporation Information
6.3.2 Mallinckrodt Description and Business Overview
6.3.3 Mallinckrodt Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Mallinckrodt Radiopharmaceutical (Oral Route) Product Portfolio
6.3.5 Mallinckrodt Recent Developments/Updates
6.4 Nordion
6.4.1 Nordion Corporation Information
6.4.2 Nordion Description and Business Overview
6.4.3 Nordion Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Nordion Radiopharmaceutical (Oral Route) Product Portfolio
6.4.5 Nordion Recent Developments/Updates
6.5 Triad Isotopes
6.5.1 Triad Isotopes Corporation Information
6.5.2 Triad Isotopes Description and Business Overview
6.5.3 Triad Isotopes Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Triad Isotopes Radiopharmaceutical (Oral Route) Product Portfolio
6.5.5 Triad Isotopes Recent Developments/Updates
6.6 Lantheus
6.6.1 Lantheus Corporation Information
6.6.2 Lantheus Description and Business Overview
6.6.3 Lantheus Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Lantheus Radiopharmaceutical (Oral Route) Product Portfolio
6.6.5 Lantheus Recent Developments/Updates
6.7 IBA Group
6.6.1 IBA Group Corporation Information
6.6.2 IBA Group Description and Business Overview
6.6.3 IBA Group Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 IBA Group Radiopharmaceutical (Oral Route) Product Portfolio
6.7.5 IBA Group Recent Developments/Updates
6.8 GE Healthcare
6.8.1 GE Healthcare Corporation Information
6.8.2 GE Healthcare Description and Business Overview
6.8.3 GE Healthcare Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.8.4 GE Healthcare Radiopharmaceutical (Oral Route) Product Portfolio
6.8.5 GE Healthcare Recent Developments/Updates
6.9 China Isotope & Radiation
6.9.1 China Isotope & Radiation Corporation Information
6.9.2 China Isotope & Radiation Description and Business Overview
6.9.3 China Isotope & Radiation Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.9.4 China Isotope & Radiation Radiopharmaceutical (Oral Route) Product Portfolio
6.9.5 China Isotope & Radiation Recent Developments/Updates
6.10 Jubilant Pharma
6.10.1 Jubilant Pharma Corporation Information
6.10.2 Jubilant Pharma Description and Business Overview
6.10.3 Jubilant Pharma Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Jubilant Pharma Radiopharmaceutical (Oral Route) Product Portfolio
6.10.5 Jubilant Pharma Recent Developments/Updates
6.11 Eli Lilly
6.11.1 Eli Lilly Corporation Information
6.11.2 Eli Lilly Radiopharmaceutical (Oral Route) Description and Business Overview
6.11.3 Eli Lilly Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Eli Lilly Radiopharmaceutical (Oral Route) Product Portfolio
6.11.5 Eli Lilly Recent Developments/Updates
6.12 Advanced Accelerator Applications
6.12.1 Advanced Accelerator Applications Corporation Information
6.12.2 Advanced Accelerator Applications Radiopharmaceutical (Oral Route) Description and Business Overview
6.12.3 Advanced Accelerator Applications Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Advanced Accelerator Applications Radiopharmaceutical (Oral Route) Product Portfolio
6.12.5 Advanced Accelerator Applications Recent Developments/Updates
6.13 SIEMENS
6.13.1 SIEMENS Corporation Information
6.13.2 SIEMENS Radiopharmaceutical (Oral Route) Description and Business Overview
6.13.3 SIEMENS Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.13.4 SIEMENS Radiopharmaceutical (Oral Route) Product Portfolio
6.13.5 SIEMENS Recent Developments/Updates
6.14 Dongcheng
6.14.1 Dongcheng Corporation Information
6.14.2 Dongcheng Radiopharmaceutical (Oral Route) Description and Business Overview
6.14.3 Dongcheng Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Dongcheng Radiopharmaceutical (Oral Route) Product Portfolio
6.14.5 Dongcheng Recent Developments/Updates
6.15 Navidea
6.15.1 Navidea Corporation Information
6.15.2 Navidea Radiopharmaceutical (Oral Route) Description and Business Overview
6.15.3 Navidea Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Navidea Radiopharmaceutical (Oral Route) Product Portfolio
6.15.5 Navidea Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Radiopharmaceutical (Oral Route) Industry Chain Analysis
7.2 Radiopharmaceutical (Oral Route) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Radiopharmaceutical (Oral Route) Production Mode & Process
7.4 Radiopharmaceutical (Oral Route) Sales and Marketing
7.4.1 Radiopharmaceutical (Oral Route) Sales Channels
7.4.2 Radiopharmaceutical (Oral Route) Distributors
7.5 Radiopharmaceutical (Oral Route) Customers
8 Radiopharmaceutical (Oral Route) Market Dynamics
8.1 Radiopharmaceutical (Oral Route) Industry Trends
8.2 Radiopharmaceutical (Oral Route) Market Drivers
8.3 Radiopharmaceutical (Oral Route) Market Challenges
8.4 Radiopharmaceutical (Oral Route) Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Radiopharmaceutical (Oral Route) Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Radiopharmaceutical (Oral Route) Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Radiopharmaceutical (Oral Route) Market Competitive Situation by Manufacturers in 2023
Table 4. Global Radiopharmaceutical (Oral Route) Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Radiopharmaceutical (Oral Route) Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Radiopharmaceutical (Oral Route) Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Radiopharmaceutical (Oral Route) Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Radiopharmaceutical (Oral Route) Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Radiopharmaceutical (Oral Route), Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Radiopharmaceutical (Oral Route), Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Radiopharmaceutical (Oral Route), Product Type & Application
Table 12. Global Key Manufacturers of Radiopharmaceutical (Oral Route), Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Radiopharmaceutical (Oral Route) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radiopharmaceutical (Oral Route) as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Radiopharmaceutical (Oral Route) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Radiopharmaceutical (Oral Route) Sales by Region (2019-2024) & (K Units)
Table 18. Global Radiopharmaceutical (Oral Route) Sales Market Share by Region (2019-2024)
Table 19. Global Radiopharmaceutical (Oral Route) Sales by Region (2025-2030) & (K Units)
Table 20. Global Radiopharmaceutical (Oral Route) Sales Market Share by Region (2025-2030)
Table 21. Global Radiopharmaceutical (Oral Route) Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Region (2019-2024)
Table 23. Global Radiopharmaceutical (Oral Route) Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Region (2025-2030)
Table 25. North America Radiopharmaceutical (Oral Route) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Radiopharmaceutical (Oral Route) Sales by Country (2019-2024) & (K Units)
Table 27. North America Radiopharmaceutical (Oral Route) Sales by Country (2025-2030) & (K Units)
Table 28. North America Radiopharmaceutical (Oral Route) Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Radiopharmaceutical (Oral Route) Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Radiopharmaceutical (Oral Route) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Radiopharmaceutical (Oral Route) Sales by Country (2019-2024) & (K Units)
Table 32. Europe Radiopharmaceutical (Oral Route) Sales by Country (2025-2030) & (K Units)
Table 33. Europe Radiopharmaceutical (Oral Route) Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Radiopharmaceutical (Oral Route) Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Radiopharmaceutical (Oral Route) Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Radiopharmaceutical (Oral Route) Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Radiopharmaceutical (Oral Route) Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Radiopharmaceutical (Oral Route) Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Radiopharmaceutical (Oral Route) Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Radiopharmaceutical (Oral Route) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Radiopharmaceutical (Oral Route) Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Radiopharmaceutical (Oral Route) Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Radiopharmaceutical (Oral Route) Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Radiopharmaceutical (Oral Route) Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Radiopharmaceutical (Oral Route) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Radiopharmaceutical (Oral Route) Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Radiopharmaceutical (Oral Route) Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Radiopharmaceutical (Oral Route) Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Radiopharmaceutical (Oral Route) Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Radiopharmaceutical (Oral Route) Sales (K Units) by Type (2019-2024)
Table 51. Global Radiopharmaceutical (Oral Route) Sales (K Units) by Type (2025-2030)
Table 52. Global Radiopharmaceutical (Oral Route) Sales Market Share by Type (2019-2024)
Table 53. Global Radiopharmaceutical (Oral Route) Sales Market Share by Type (2025-2030)
Table 54. Global Radiopharmaceutical (Oral Route) Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Radiopharmaceutical (Oral Route) Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Type (2019-2024)
Table 57. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Type (2025-2030)
Table 58. Global Radiopharmaceutical (Oral Route) Price (US$/Unit) by Type (2019-2024)
Table 59. Global Radiopharmaceutical (Oral Route) Price (US$/Unit) by Type (2025-2030)
Table 60. Global Radiopharmaceutical (Oral Route) Sales (K Units) by Application (2019-2024)
Table 61. Global Radiopharmaceutical (Oral Route) Sales (K Units) by Application (2025-2030)
Table 62. Global Radiopharmaceutical (Oral Route) Sales Market Share by Application (2019-2024)
Table 63. Global Radiopharmaceutical (Oral Route) Sales Market Share by Application (2025-2030)
Table 64. Global Radiopharmaceutical (Oral Route) Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Radiopharmaceutical (Oral Route) Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Application (2019-2024)
Table 67. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Application (2025-2030)
Table 68. Global Radiopharmaceutical (Oral Route) Price (US$/Unit) by Application (2019-2024)
Table 69. Global Radiopharmaceutical (Oral Route) Price (US$/Unit) by Application (2025-2030)
Table 70. Bracco Imaging Corporation Information
Table 71. Bracco Imaging Description and Business Overview
Table 72. Bracco Imaging Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Bracco Imaging Radiopharmaceutical (Oral Route) Product
Table 74. Bracco Imaging Recent Developments/Updates
Table 75. Bayer Corporation Information
Table 76. Bayer Description and Business Overview
Table 77. Bayer Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Bayer Radiopharmaceutical (Oral Route) Product
Table 79. Bayer Recent Developments/Updates
Table 80. Mallinckrodt Corporation Information
Table 81. Mallinckrodt Description and Business Overview
Table 82. Mallinckrodt Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Mallinckrodt Radiopharmaceutical (Oral Route) Product
Table 84. Mallinckrodt Recent Developments/Updates
Table 85. Nordion Corporation Information
Table 86. Nordion Description and Business Overview
Table 87. Nordion Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Nordion Radiopharmaceutical (Oral Route) Product
Table 89. Nordion Recent Developments/Updates
Table 90. Triad Isotopes Corporation Information
Table 91. Triad Isotopes Description and Business Overview
Table 92. Triad Isotopes Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Triad Isotopes Radiopharmaceutical (Oral Route) Product
Table 94. Triad Isotopes Recent Developments/Updates
Table 95. Lantheus Corporation Information
Table 96. Lantheus Description and Business Overview
Table 97. Lantheus Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Lantheus Radiopharmaceutical (Oral Route) Product
Table 99. Lantheus Recent Developments/Updates
Table 100. IBA Group Corporation Information
Table 101. IBA Group Description and Business Overview
Table 102. IBA Group Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. IBA Group Radiopharmaceutical (Oral Route) Product
Table 104. IBA Group Recent Developments/Updates
Table 105. GE Healthcare Corporation Information
Table 106. GE Healthcare Description and Business Overview
Table 107. GE Healthcare Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. GE Healthcare Radiopharmaceutical (Oral Route) Product
Table 109. GE Healthcare Recent Developments/Updates
Table 110. China Isotope & Radiation Corporation Information
Table 111. China Isotope & Radiation Description and Business Overview
Table 112. China Isotope & Radiation Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. China Isotope & Radiation Radiopharmaceutical (Oral Route) Product
Table 114. China Isotope & Radiation Recent Developments/Updates
Table 115. Jubilant Pharma Corporation Information
Table 116. Jubilant Pharma Description and Business Overview
Table 117. Jubilant Pharma Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Jubilant Pharma Radiopharmaceutical (Oral Route) Product
Table 119. Jubilant Pharma Recent Developments/Updates
Table 120. Eli Lilly Corporation Information
Table 121. Eli Lilly Description and Business Overview
Table 122. Eli Lilly Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Eli Lilly Radiopharmaceutical (Oral Route) Product
Table 124. Eli Lilly Recent Developments/Updates
Table 125. Advanced Accelerator Applications Corporation Information
Table 126. Advanced Accelerator Applications Description and Business Overview
Table 127. Advanced Accelerator Applications Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. Advanced Accelerator Applications Radiopharmaceutical (Oral Route) Product
Table 129. Advanced Accelerator Applications Recent Developments/Updates
Table 130. SIEMENS Corporation Information
Table 131. SIEMENS Description and Business Overview
Table 132. SIEMENS Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. SIEMENS Radiopharmaceutical (Oral Route) Product
Table 134. SIEMENS Recent Developments/Updates
Table 135. Dongcheng Corporation Information
Table 136. Dongcheng Description and Business Overview
Table 137. Dongcheng Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 138. Dongcheng Radiopharmaceutical (Oral Route) Product
Table 139. Dongcheng Recent Developments/Updates
Table 140. Navidea Corporation Information
Table 141. Navidea Description and Business Overview
Table 142. Navidea Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 143. Navidea Radiopharmaceutical (Oral Route) Product
Table 144. Navidea Recent Developments/Updates
Table 145. Key Raw Materials Lists
Table 146. Raw Materials Key Suppliers Lists
Table 147. Radiopharmaceutical (Oral Route) Distributors List
Table 148. Radiopharmaceutical (Oral Route) Customers List
Table 149. Radiopharmaceutical (Oral Route) Market Trends
Table 150. Radiopharmaceutical (Oral Route) Market Drivers
Table 151. Radiopharmaceutical (Oral Route) Market Challenges
Table 152. Radiopharmaceutical (Oral Route) Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Radiopharmaceutical (Oral Route)
Figure 2. Global Radiopharmaceutical (Oral Route) Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Radiopharmaceutical (Oral Route) Market Share by Type in 2023 & 2030
Figure 4. Actinium-225 Product Picture
Figure 5. Lutetium-177 Product Picture
Figure 6. Radium-223 Product Picture
Figure 7. Holmium-166 Product Picture
Figure 8. Other Product Picture
Figure 9. Global Radiopharmaceutical (Oral Route) Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 10. Global Radiopharmaceutical (Oral Route) Market Share by Application in 2023 & 2030
Figure 11. Oncology
Figure 12. Cardiology
Figure 13. Other
Figure 14. Global Radiopharmaceutical (Oral Route) Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Radiopharmaceutical (Oral Route) Market Size (2019-2030) & (US$ Million)
Figure 16. Global Radiopharmaceutical (Oral Route) Sales (2019-2030) & (K Units)
Figure 17. Global Radiopharmaceutical (Oral Route) Average Price (US$/Unit) & (2019-2030)
Figure 18. Radiopharmaceutical (Oral Route) Report Years Considered
Figure 19. Radiopharmaceutical (Oral Route) Sales Share by Manufacturers in 2023
Figure 20. Global Radiopharmaceutical (Oral Route) Revenue Share by Manufacturers in 2023
Figure 21. The Global 5 and 10 Largest Radiopharmaceutical (Oral Route) Players: Market Share by Revenue in 2023
Figure 22. Radiopharmaceutical (Oral Route) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 23. Global Radiopharmaceutical (Oral Route) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 24. North America Radiopharmaceutical (Oral Route) Sales Market Share by Country (2019-2030)
Figure 25. North America Radiopharmaceutical (Oral Route) Revenue Market Share by Country (2019-2030)
Figure 26. United States Radiopharmaceutical (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. Canada Radiopharmaceutical (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. Europe Radiopharmaceutical (Oral Route) Sales Market Share by Country (2019-2030)
Figure 29. Europe Radiopharmaceutical (Oral Route) Revenue Market Share by Country (2019-2030)
Figure 30. Germany Radiopharmaceutical (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. France Radiopharmaceutical (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. U.K. Radiopharmaceutical (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Italy Radiopharmaceutical (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Russia Radiopharmaceutical (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Asia Pacific Radiopharmaceutical (Oral Route) Sales Market Share by Region (2019-2030)
Figure 36. Asia Pacific Radiopharmaceutical (Oral Route) Revenue Market Share by Region (2019-2030)
Figure 37. China Radiopharmaceutical (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Japan Radiopharmaceutical (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. South Korea Radiopharmaceutical (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. India Radiopharmaceutical (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Australia Radiopharmaceutical (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. China Taiwan Radiopharmaceutical (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Indonesia Radiopharmaceutical (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Thailand Radiopharmaceutical (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Malaysia Radiopharmaceutical (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Latin America Radiopharmaceutical (Oral Route) Sales Market Share by Country (2019-2030)
Figure 47. Latin America Radiopharmaceutical (Oral Route) Revenue Market Share by Country (2019-2030)
Figure 48. Mexico Radiopharmaceutical (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Brazil Radiopharmaceutical (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Argentina Radiopharmaceutical (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Middle East & Africa Radiopharmaceutical (Oral Route) Sales Market Share by Country (2019-2030)
Figure 52. Middle East & Africa Radiopharmaceutical (Oral Route) Revenue Market Share by Country (2019-2030)
Figure 53. Turkey Radiopharmaceutical (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. Saudi Arabia Radiopharmaceutical (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. UAE Radiopharmaceutical (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 56. Global Sales Market Share of Radiopharmaceutical (Oral Route) by Type (2019-2030)
Figure 57. Global Revenue Market Share of Radiopharmaceutical (Oral Route) by Type (2019-2030)
Figure 58. Global Radiopharmaceutical (Oral Route) Price (US$/Unit) by Type (2019-2030)
Figure 59. Global Sales Market Share of Radiopharmaceutical (Oral Route) by Application (2019-2030)
Figure 60. Global Revenue Market Share of Radiopharmaceutical (Oral Route) by Application (2019-2030)
Figure 61. Global Radiopharmaceutical (Oral Route) Price (US$/Unit) by Application (2019-2030)
Figure 62. Radiopharmaceutical (Oral Route) Value Chain
Figure 63. Radiopharmaceutical (Oral Route) Production Process
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Distributors Profiles
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
